Persistence of transcriptionally silent BCR-ABL rearrangements in chronic myeloid leukemia patients in sustained complete cytogenetic remission

Leukemia and Lymphoma

Volumn 42, Issue 5, 2001, Pages 933-944

  Kitzis, A ^a   Brizard, F ^a   Dascalescu, C ^a   Chomel, J C ^a   Guilhot, F ^a   Brizard, A ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

BCR ABL rearrangement; Chronic myeloid leukemia; Complete cytogenetic remission; Fluorescence in situ hybridization; Polymerase chain reaction

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; DNA; RNA;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; BONE MARROW BIOPSY; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE EXPRESSION; GENE REARRANGEMENT; GENETIC TRANSCRIPTION; HUMAN; HYPOTHESIS; INTERPHASE; LEUKEMIA REMISSION; MEDICAL DECISION MAKING; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SILENT GENE; SOUTHERN BLOTTING;

EID: 0034846490     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109097712     Document Type: Article

References (74)

1. Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage
2. A minute chromosome in human chronic granulocytic leukemia
3. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
4. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
5. The molecular biology of chronic myeloid leukemia
6. Treatment of chronic myelogenous leukemia: Current status and investigational options
7. Cytogenetic remissions in chronic myelogenous leukemia using interferon alpha2a and hydroxyurea with or without low dose cytosine-arabinoside
8. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
9. Review: An evidence-based analysis of the effect of Busulfan, Hydroxyurea. Interferon and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the Hematology
10. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine
11. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy
12. Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia
13. Molecular monitoring of residual disease in chronic myelogenous leukemia patients after therapy
14. Minimal residual disease in chronic myeloid leukemia
15. Hypermetaphase FISH for quantitative monitoring of Ph-positive cells in patients with CML
16. Philadelphia chromosome-possitive myeloid cells in the peripheral blood of chronic myelogenous leukemia patients: Comparison with the frequency detected in cycling cells of the bone marrow
17. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myelogenous leukemia
18. A special fluorescent in situ hybridization technique to study peripheral blood and asses the effectiveness of interferon therapy in chronic myelogenous leukemia
19. Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders
20. Does BCR-ABL genomic rearrangement persist in CML patients in complete remission after interferon-α therapy?
21. Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic-myeloid leukemia during interferon-α therapy
22. Fluorescence in situ hybridization for the BCR/ABL rearrangement is dependent on the percentage of nonlymphocytic cells in peripheral blood stem cell harvests
23. The application of fluorescent in situ hybridization to detect Mbcr/abl fusion in variant Ph chromosomes in CML and ALL
24. Detection of minimal residual disease state in chronic myelogenous leukemia patients using fluorescence in situ hybridization
25. Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization
26. FISH analysis for CML monitoring?
27. Detection of the Mbcr/abl translocation in chronic myeloid leukemia by fluorescence in situ hybridization: Comparison with conventional cytogenetics and implications of minimal residual disease detection
28. Value of fluorescence in situ hybridization for detecting the bcr/abl gene fusion in interphase cells of routine bone marrow specimens
29. Simple and reliable sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells
30. Persistence of BCR-ABL genomic rearrangements in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-α therapy or allogeneic bone marrow transplantation
31. Monitoring and prognostic evaluation of sex mismatched bone marrow transplantation by competitive PCR on Y chromosome sequences
32. Persistence of BCR-ABL genomic rearrangements in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-α therapy or allogeneic bone marrow transplantation
33. A multicenter investigation with D-FISH BCR/ABL1 probes
34. A two color bcr-abl probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia
35. Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia
36. Densitometric analysis of Southern blot autoradiographs and its application to monitoring patients with chronic myeloid leukemia
37. Quantification of residual disease in chronic myelogenous leukemia patients on Interferon-alpha therapy by competitive polymerase chain reaction
38. Absence of host-derived cells in the blood of patients in remission after allografting for chronic myeloid leukemia
39. A multicenter investigation with interphase fluorescence in situ hybridization using X- and Y-chromosome probes
40. No evidence of persistence of BCR-ABL-positive cells in patients in molecular remission after conventional allogeneic transplantation for chronic myeloid leukemia
41. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation
42. Long-template DNA polymerase chain reaction for the detection of the bcr-abl translocation in patients with chronic myelogenous leukemia
43. Benign marrow progenitors are enriched in the CD34+/HLA-DR1o population but not in the CD34+/CD381o population in chronic myeloid leukemia: An analysis using interphase fluorescence in situ hybridization
44. BCR-ABL negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients
45. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia
46. Identification of BCR-ABL negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow
47. Variable transcription of BCR-ABL by Ph+ cells arising from hematopoietic progenitors in chronic myeloid leukemia
48. Interferon response in chronic myeloid leukemia correlates with ABL-BCR expression: A preliminary study
49. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukemia: A metaphase-FISH study
50. BCR-ABL expression in different subpopulations of functionnally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia
51. Molecular analysis of hematopoietic colonies derived from chronic myeloid leukemia patients: Interphase fluorescence in situ hybridization compared with RT-PCR
52. Evidence from a leukaemia model for maintenance of vascular endothelium by bone marrow derived endothelial cells
53. Persistence of myeloid progenitor cells expressing bcr-abl mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia
54. Bcr-abl positive and negative clonogenic cells in CML patiens undergoing long-term interferon treatment
55. Persistence of dormant leukemic progenitors during interferon induced remission in chronic myelogenous leukemia
56. Bcr-abl-positive progenitors in chronic myeloid leukemia patients in complete cytogenetic remission after treatment with interferon-α
57. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: Comparison with cytogenetics and PCR from uncultured cells
58. Isolation of a highly quiescent sub population of primitive leukemic cells in chronic myeloid leukemia
59. Cancer dormancy: Opportunities for new therapeutic approaches
60. Tumor-suppresor genes: News about the interferon connection
61. The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell-regulated manner
62. Interferon-a: Mechanisms of action in chronic myelogenous leukemia in chronic phase
63. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
64. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion
65. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia
66. Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon
67. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals
68. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease
69. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: Where we now stand
70. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia
71. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: Results and implications in 346 patients
72. Monitoring chronic myeloide leukaemia therapy by real-time quantiative PCR in blood is a reliable alternative to bone marrow cytogenetics
73. Detetion of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a real time quantitative RT-PCR assay
74. Molecular heterogeneity in complete cytogenetic responders after interferon-a therapy for chronic myelogenous leukemia: Low levels of minimal residual disease are associated with continuing remission